Fluzoparib | SHR3162 | PARP1 Inhibitor | AmBeed-信号通路专用抑制剂

Fluzoparib/氟唑帕利 {[allProObj[0].p_purity_real_show]}

货号：A1474773 同义名： SHR3162; Fuzuloparib

Fluzoparib是一种口服有效的 PARP1 抑制剂，能够选择性地抑制 DNA 修复机制。它在癌症治疗中展现了优异的抗肿瘤活性。

Fluzoparib/氟唑帕利化学结构
CAS号：1358715-18-0

Fluzoparib/氟唑帕利 3D分子结构
CAS号：1358715-18-0

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]}	现货	1周咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Fluzoparib/氟唑帕利纯度/质量文件产品仅供科研

货号：A1474773 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Nature, 2025, 645, 793-800. Ambeed. [ A201204 , A444152 , A344107 , A952055 ]; • Cell, 2025. Ambeed. [ A122167 ]; • Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]; • Sig. Transduct. Target. Ther., 2025, 10, 257. Ambeed. [ A104916 ]; • Nat. Nanotechnol., 2025. Ambeed. [ A243018 , A1216705 , A522597 , A125401 , A1355641 ]; 更多 >

Fluzoparib/氟唑帕利质控信息

PARP 亚型比较

产品名称	PARP ↓ ↑	PARP1 ↓ ↑	PARP2 ↓ ↑	PARP3 ↓ ↑	纯度
PJ34 HCl	++ PARP, EC50: 20 nM				99%+
Rucaparib phosphate	++++ PARP, Ki: 1.4 nM				99%+
3-Aminobenzamide	++ PARP, IC50: <50 nM				98%
AZD-2461	✔				99%+
BGP-15	✔				99%+
NU1025	+ PARP, IC50: 400 nM				98%
Benzamide	+ PARP, IC50: 3.3 μM				98%
Picolinamide	+ PARP, IC50: 95 μM				98%
AG14361		+++ PARP1, Ki: <5 nM			98+%
Iniparib		✔			98%
Talazoparib		++++ PARP1, IC50: 0.57 nM			99%+
NMS-P118		++ PARP1, Kd: 0.009 μM			97%
UPF 1069		+ PARP1, IC50: 8.0 μM	++ PARP2, IC50: 0.3 μM		98%
A-966492		++++ PARP1, EC50: 1 nM PARP1, Ki: 1 nM	+++ PARP2, Ki: 1.5 nM		99%+
Veliparib		++ PARP1, Ki: 5.2 nM	+++ PARP2, Ki: 2.9 nM		98%
Niraparib tosylate		+++ PARP1, IC50: 3.8 nM	+++ PARP2, IC50: 2.1 nM		99%+
Stenoparib		++++ PARP1, IC50: 1 nM	++++ PARP2, IC50: 1.2 nM		98%
Olaparib		+++ PARP1, IC50: 5 nM	++++ PARP2, IC50: 1 nM		98%
Niraparib		+++ PARP1, IC50: 3.8 nM	+++ PARP2, IC50: 2.1 nM		98%
ME0328		+ PARP1, IC50: 6.3 μM		+ PARP3, IC50: 0.89 μM	99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Fluzoparib/氟唑帕利细胞实验

Cell Line MDA-MB-231 GBC-SD OVCA433 DOV13 BT-549 HCCC-9810 MDA-MB-468-FR HCC1937-FR MDA-MB-468 HCC1937 NCI–H929B (H929B, bortezomib-resistant) NCI–H929 (H929)	Concentration	Treated Time	Description	References
MDA-MB-231	2.5 µM	3 h	Inhibition of H2O2-induced PARylation	Am J Cancer Res. 2019 Mar 1;9(3):608-618
GBC-SD	5 μM	4 hours	Inhibited cell proliferation and enhanced radiosensitivity	Cancer Manag Res. 2020 Nov 19;12:11833-11844
OVCA433	5 µM	3 h	Inhibition of H2O2-induced PARylation	Am J Cancer Res. 2019 Mar 1;9(3):608-618
DOV13	625 nM	3 h	Inhibition of H2O2-induced PARylation	Am J Cancer Res. 2019 Mar 1;9(3):608-618
BT-549	625 nM	3 h	Inhibition of H2O2-induced PARylation	Am J Cancer Res. 2019 Mar 1;9(3):608-618
HCCC-9810	10 μM	4 hours	Inhibited cell proliferation and enhanced radiosensitivity	Cancer Manag Res. 2020 Nov 19;12:11833-11844
MDA-MB-468-FR	80 mg/ml	48 hours	Evaluate the cytotoxicity of Fluzoparib on drug-resistant MDA-MB-468-FR cells, results showed that the viability of drug-resistant cells was significantly higher than that of parental cells	Front Oncol. 2022 Feb 18;12:819714
HCC1937-FR	60 mg/ml	48 hours	Evaluate the cytotoxicity of Fluzoparib on drug-resistant HCC1937-FR cells, results showed that the viability of drug-resistant cells was significantly higher than that of parental cells	Front Oncol. 2022 Feb 18;12:819714
MDA-MB-468	15 mg/ml	48 hours	Evaluate the cytotoxicity of Fluzoparib on MDA-MB-468 cells, results showed that cell growth was significantly reduced with increasing Fluzoparib concentration	Front Oncol. 2022 Feb 18;12:819714
HCC1937	6 mg/ml	48 hours	Evaluate the cytotoxicity of Fluzoparib on HCC1937 cells, results showed that cell growth was significantly reduced with increasing Fluzoparib concentration	Front Oncol. 2022 Feb 18;12:819714
NCI–H929B (H929B, bortezomib-resistant)	2.5, 5, 10 nM	24 hours	To evaluate the effect of Fluzoparib on the viability and apoptosis of drug-resistant MM cells. Results showed that Fluzoparib significantly inhibited the proliferation of H929B cells and induced apoptosis.	Biochem Biophys Rep. 2024 Jul 7;39:101781
NCI–H929 (H929)	2.5, 5, 10 nM	24 hours	To evaluate the effect of Fluzoparib on the viability and apoptosis of MM cells. Results showed that Fluzoparib significantly inhibited the proliferation of H929 and H929B cells and induced apoptosis.	Biochem Biophys Rep. 2024 Jul 7;39:101781

Cell Line

Concentration

Treated Time

Description

References

MDA-MB-231

2.5 µM

3 h

Inhibition of H2O2-induced PARylation

Am J Cancer Res. 2019 Mar 1;9(3):608-618

GBC-SD

5 μM

4 hours

Inhibited cell proliferation and enhanced radiosensitivity

Cancer Manag Res. 2020 Nov 19;12:11833-11844

OVCA433

5 µM

3 h

Inhibition of H2O2-induced PARylation

Am J Cancer Res. 2019 Mar 1;9(3):608-618

DOV13

625 nM

3 h

Inhibition of H2O2-induced PARylation

Am J Cancer Res. 2019 Mar 1;9(3):608-618

BT-549

625 nM

3 h

Inhibition of H2O2-induced PARylation

Am J Cancer Res. 2019 Mar 1;9(3):608-618

HCCC-9810

10 μM

4 hours

Inhibited cell proliferation and enhanced radiosensitivity

Cancer Manag Res. 2020 Nov 19;12:11833-11844

MDA-MB-468-FR

80 mg/ml

48 hours

Evaluate the cytotoxicity of Fluzoparib on drug-resistant MDA-MB-468-FR cells, results showed that the viability of drug-resistant cells was significantly higher than that of parental cells

Front Oncol. 2022 Feb 18;12:819714

HCC1937-FR

60 mg/ml

48 hours

Evaluate the cytotoxicity of Fluzoparib on drug-resistant HCC1937-FR cells, results showed that the viability of drug-resistant cells was significantly higher than that of parental cells

Front Oncol. 2022 Feb 18;12:819714

MDA-MB-468

15 mg/ml

48 hours

Evaluate the cytotoxicity of Fluzoparib on MDA-MB-468 cells, results showed that cell growth was significantly reduced with increasing Fluzoparib concentration

Front Oncol. 2022 Feb 18;12:819714

HCC1937

6 mg/ml

48 hours

Evaluate the cytotoxicity of Fluzoparib on HCC1937 cells, results showed that cell growth was significantly reduced with increasing Fluzoparib concentration

Front Oncol. 2022 Feb 18;12:819714

NCI–H929B (H929B, bortezomib-resistant)

2.5, 5, 10 nM

24 hours

To evaluate the effect of Fluzoparib on the viability and apoptosis of drug-resistant MM cells. Results showed that Fluzoparib significantly inhibited the proliferation of H929B cells and induced apoptosis.

Biochem Biophys Rep. 2024 Jul 7;39:101781

NCI–H929 (H929)

2.5, 5, 10 nM

24 hours

To evaluate the effect of Fluzoparib on the viability and apoptosis of MM cells. Results showed that Fluzoparib significantly inhibited the proliferation of H929 and H929B cells and induced apoptosis.

Biochem Biophys Rep. 2024 Jul 7;39:101781

Fluzoparib/氟唑帕利动物实验

Species BALB/c nude mice BALB/c nude mice	Animal Model HCC1937-FR xenograft model Subcutaneous MM tumor model	Administration	Dosage	Frequency	Description	References
BALB/c nude mice	HCC1937-FR xenograft model	Subcutaneous injection	25 mg/kg/bid (Fluzoparib), 5 mg/kg/bw (Chidamide)	Twice daily for 21 days	Evaluate the antitumor effects of Fluzoparib and Chidamide on HCC1937-FR xenograft model, results showed that the combination significantly inhibited tumor growth	Front Oncol. 2022 Feb 18;12:819714
BALB/c nude mice	Subcutaneous MM tumor model	Oral	30 mg/kg	Once daily for 13 days	To evaluate the inhibitory effect of Fluzoparib on MM tumor growth in vivo. Results showed that Fluzoparib significantly suppressed tumor volumes and weights and promoted apoptosis of tumor tissue.	Biochem Biophys Rep. 2024 Jul 7;39:101781

Species

BALB/c nude mice BALB/c nude mice

Animal Model

HCC1937-FR xenograft model Subcutaneous MM tumor model

Administration

Dosage

Frequency

Description

References

BALB/c nude mice

HCC1937-FR xenograft model

Subcutaneous injection

25 mg/kg/bid (Fluzoparib), 5 mg/kg/bw (Chidamide)

Twice daily for 21 days

Evaluate the antitumor effects of Fluzoparib and Chidamide on HCC1937-FR xenograft model, results showed that the combination significantly inhibited tumor growth

Front Oncol. 2022 Feb 18;12:819714

BALB/c nude mice

Subcutaneous MM tumor model

Oral

30 mg/kg

Once daily for 13 days

To evaluate the inhibitory effect of Fluzoparib on MM tumor growth in vivo. Results showed that Fluzoparib significantly suppressed tumor volumes and weights and promoted apoptosis of tumor tissue.

Biochem Biophys Rep. 2024 Jul 7;39:101781

Fluzoparib/氟唑帕利实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.12mL

0.42mL

0.21mL

10.58mL

2.12mL

1.06mL

21.17mL

4.23mL

2.12mL

Fluzoparib/氟唑帕利技术信息

CAS号	1358715-18-0
分子式	C₂₂H₁₆F₄N₆O₂
分子量	472.4
SMILES Code	O=C1NN=C(CC2=CC=C(F)C(C(N3CC4=NC(C(F)(F)F)=NN4CC3)=O)=C2)C5=C1C=CC=C5
MDL No.	MFCD32899277

别名	SHR3162; Fuzuloparib; HS10160
运输	蓝冰

存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Sealed in dry, store in freezer, under -20°C

溶解方案

细胞实验：

DMSO: 35 mg/mL(74.09 mM)，配合低频超声，并水浴加热至45℃助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验：请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

方案二

Fluzoparib/氟唑帕利 {[allProObj[0].p_purity_real_show]}

Fluzoparib/氟唑帕利纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Fluzoparib/氟唑帕利质控信息

Fluzoparib/氟唑帕利细胞实验

Fluzoparib/氟唑帕利动物实验

Fluzoparib/氟唑帕利实验方案

Fluzoparib/氟唑帕利技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Fluzoparib/氟唑帕利 {[allProObj[0].p_purity_real_show]}

Fluzoparib/氟唑帕利 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Fluzoparib/氟唑帕利 质控信息

Fluzoparib/氟唑帕利 细胞实验

Fluzoparib/氟唑帕利 动物实验

Fluzoparib/氟唑帕利 实验方案

Fluzoparib/氟唑帕利 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Fluzoparib/氟唑帕利纯度/质量文件产品仅供科研

Fluzoparib/氟唑帕利质控信息

Fluzoparib/氟唑帕利细胞实验

Fluzoparib/氟唑帕利动物实验

Fluzoparib/氟唑帕利实验方案

Fluzoparib/氟唑帕利技术信息